What Is the Best Initial Imaging for Pretreatment Staging of Vaginal Cancer? An ACR-Guided Workflow

May 29, 2026 · Pouyan Golshani, MD, Interventional Radiologist

A 68-year-old woman presents to your gynecologic oncology clinic with postmenopausal bleeding. A speculum exam reveals a 3 cm ulcerated lesion in the upper third of the vaginal wall, and a subsequent biopsy confirms invasive squamous cell carcinoma. The diagnosis is made, but the critical next step is determining the extent of the disease to formulate a treatment plan. You need to order the right initial imaging study to accurately stage the cancer, assessing local invasion, nodal involvement, and the possibility of distant spread. This article provides a detailed workflow for this specific clinical scenario: initial pretreatment staging of primary vaginal cancer. According to the American College of Radiology (ACR) Appropriateness Criteria, MRI pelvis without and with IV contrast is rated Usually Appropriate as the primary imaging modality in this setting.

Who Fits This Clinical Scenario for Vaginal Cancer Staging?

This guidance is specifically for clinicians managing a patient with a new, biopsy-proven diagnosis of primary vaginal cancer before any treatment has been initiated. The primary goal of imaging in this context is to establish the baseline clinical stage, which is essential for determining the appropriate therapeutic approach, whether it be radiation, chemotherapy, surgery, or a combination.

This workflow applies to patients where the key clinical question is the initial extent of a newly diagnosed primary vaginal tumor.

It is crucial to distinguish this from similar but distinct clinical situations that require different imaging strategies:

Post-treatment surveillance: This article does not apply to patients who have already completed therapy and are undergoing routine follow-up imaging without any symptoms of recurrence. That scenario is covered in the ACR variant for posttreatment evaluation with no suspected recurrence.
Suspected recurrence: If a patient who was previously treated for vaginal cancer now presents with new symptoms (e.g., pain, bleeding, a palpable mass) concerning for recurrence, the imaging workup is different. This falls under the ACR variant for evaluating suspected or known recurrence.
Metastatic disease to the vagina: This guidance is for primary vaginal cancer. If the vaginal tumor is a metastasis from another cancer (e.g., cervical, endometrial, colorectal, or bladder), the imaging strategy is dictated by the primary malignancy’s staging guidelines.

What Are You Evaluating During Initial Staging?

Once primary vaginal cancer is confirmed by biopsy, imaging is not used for diagnosis but for staging. The goal is to answer specific questions about the tumor’s extent, which directly corresponds to the FIGO (International Federation of Gynecology and Obstetrics) staging system. The imaging study must be capable of assessing the following.

Local Tumor Extent (T-stage): This is the most critical information sought from initial pelvic imaging. The radiologist will evaluate the tumor’s size and, most importantly, its relationship to adjacent structures. Key questions include: Has the tumor invaded through the vaginal wall into the surrounding fatty tissue (paracolpium)? Does it extend to the pelvic sidewall? Is there direct invasion into the bladder anteriorly or the rectum posteriorly? The answers to these questions determine the tumor’s T-stage and are a primary driver of treatment decisions.

Regional Nodal Metastasis (N-stage): The next step is to assess for spread to regional lymph nodes. For vaginal cancer, this includes the pelvic lymph nodes (obturator, internal and external iliac) and, depending on the tumor’s location (especially in the lower third of the vagina), the inguinal lymph nodes. Imaging identifies nodes that are enlarged or have suspicious features, which would upstage the disease and significantly alter the treatment plan, typically necessitating the inclusion of nodal basins in the radiation field.

Distant Metastasis (M-stage): While pelvic imaging is the focus for local staging, clinicians must also consider the risk of distant disease. For locally advanced tumors or those with suspicious lymph nodes, a more comprehensive whole-body imaging study is often required to rule out metastases to the lungs, liver, bones, or distant lymph nodes. The initial pelvic study can sometimes provide the justification for this next step.

Why Is Pelvic MRI with Contrast the Recommended Study for Initial Staging?

The ACR panel designates MRI pelvis without and with IV contrast as Usually Appropriate because of its unparalleled ability to define local tumor extent, which is the cornerstone of accurate staging and treatment planning for vaginal cancer.

The primary advantage of MRI is its superior soft-tissue contrast resolution. It can clearly delineate the layers of the vaginal wall and distinguish the tumor from normal surrounding tissues like the bladder, rectum, and pelvic floor muscles. T2-weighted sequences, in particular, are excellent for visualizing the tumor’s margins and assessing for invasion into adjacent structures. This level of detail is critical for differentiating between FIGO stage I (tumor confined to the vagina), stage II (invading paravaginal tissues but not the pelvic wall), stage III (extending to the pelvic wall), and stage IVA (invading bladder or rectal mucosa).

The addition of intravenous gadolinium-based contrast enhances the tumor, making its borders more conspicuous and helping to identify areas of necrosis. This further improves the assessment of local invasion and can increase the detection of involved lymph nodes.

A significant benefit of MRI is the absence of ionizing radiation (adult RRL=O 0 mSv). This is particularly relevant in patients who will subsequently undergo radiation therapy, as it avoids contributing to the cumulative radiation dose to pelvic organs.

How Do Alternatives Compare?

FDG-PET/CT skull base to mid-thigh is also rated Usually Appropriate. It is superior to both MRI and CT for detecting nodal and distant metastatic disease and is often used as a complementary study for higher-risk or advanced-stage cancers. However, it has lower spatial resolution for the primary tumor itself, making it less precise than MRI for evaluating the depth of local invasion. It also involves a significant radiation dose (adult RRL=☢☢☢☢ 10-30 mSv).
CT abdomen and pelvis with IV contrast is rated Usually Appropriate but is generally considered secondary to MRI for local staging. Its soft-tissue resolution in the pelvis is inferior to MRI, making it difficult to accurately assess T-stage. CT is, however, excellent for evaluating the upper abdomen, lungs (if chest is included), and distant lymph nodes, and may be used when MRI is contraindicated or unavailable.
Transvaginal Ultrasound (US) is rated Usually Not Appropriate for staging. While useful for initial detection or biopsy guidance, its limited field of view and operator-dependent nature make it inadequate for assessing deep pelvic invasion or nodal status.

What Is the Downstream Workflow After the Initial Pelvic MRI?

The results of the initial staging MRI will guide the subsequent steps in the patient’s management, often in consultation with a multidisciplinary tumor board including gynecologic oncology, radiation oncology, and medical oncology.

If MRI shows early-stage disease (e.g., FIGO Stage I/II): For tumors confined to the vagina or with minimal paravaginal extension, the patient will typically proceed to definitive radiation therapy, often a combination of external beam radiation therapy (EBRT) and brachytherapy. The detailed anatomy provided by the MRI is used directly by the radiation oncologist to plan the treatment fields, ensuring the tumor is adequately covered while sparing nearby organs like the bladder and rectum.

If MRI shows locally advanced disease (e.g., FIGO Stage III/IVA): If the MRI demonstrates tumor extension to the pelvic sidewall or invasion of the bladder or rectum, the patient has locally advanced disease. The standard of care is definitive chemoradiation. In this situation, the MRI findings are crucial, but there is a high likelihood of nodal or distant metastatic disease. This often triggers a second imaging study, typically an FDG-PET/CT, to complete the staging workup and ensure there is no distant disease before committing to an intensive local treatment regimen.

If MRI shows suspicious lymph nodes: The presence of enlarged or necrotic-appearing pelvic or inguinal lymph nodes (N1 disease) upstages the cancer. This finding almost always necessitates the addition of FDG-PET/CT to search for other sites of disease. It also confirms the need to include the nodal basins in the radiation treatment plan.

Pitfalls to Avoid (and When to Get Help)

Accurate initial staging is critical, and several pitfalls can compromise the workup.

Omitting IV Contrast: Ordering a non-contrast MRI of the pelvis (rated May be appropriate) can significantly limit the evaluation of tumor vascularity and conspicuity, potentially leading to underestimation of the tumor’s extent. Always specify “without and with IV contrast” unless there is a clear contraindication.
Using the Wrong Modality First: Defaulting to CT for initial local staging can miss subtle invasion of the bladder or rectum that would be clearly visible on MRI, leading to under-staging and potentially inadequate treatment planning.
Inadequate Clinical History: Failing to provide the radiologist with the precise location of the tumor found on clinical exam and the biopsy results can hinder their interpretation. Specify the vaginal location (e.g., “upper third, anterior wall”) on the imaging requisition.
Ignoring Inguinal Nodes: For tumors in the distal third of the vagina, remember that the lymphatic drainage is to the inguinal nodes. Ensure the imaging field of view adequately covers this region or that they are specifically evaluated.

If the imaging findings are complex, equivocal, or discordant with the clinical exam, escalation to a multidisciplinary gynecologic cancer tumor board is the essential next step.

Frequently Asked Questions

Why is MRI preferred over PET/CT for the very first imaging study in vaginal cancer staging?

While FDG-PET/CT is excellent for detecting nodal and distant metastases, MRI provides superior soft-tissue resolution of the primary tumor and its relationship to adjacent pelvic organs like the bladder and rectum. This detail is essential for accurate local T-staging, which is a primary determinant of the treatment plan. Often, MRI is performed first to stage the local disease, and if it shows advanced features, a PET/CT is then added to complete the staging workup for distant disease.

Is there any role for CT scan in the initial staging of vaginal cancer?

Yes. While MRI is superior for local T-staging, a CT of the abdomen and pelvis with IV contrast is rated ‘Usually Appropriate’ by the ACR. It is a reasonable alternative if MRI is contraindicated (e.g., due to an incompatible medical device or severe claustrophobia) or unavailable. CT is also very effective for evaluating distant lymph nodes and organs in the abdomen and can be combined with a CT chest to assess for lung metastases.

What if my patient has a contraindication to gadolinium contrast for the MRI?

If a patient has a severe allergy or significant renal impairment precluding the use of gadolinium, a non-contrast MRI of the pelvis is rated ‘May be appropriate’. While less optimal than a contrast-enhanced study, the high-resolution T2-weighted images from a non-contrast MRI still provide excellent anatomical detail for local staging and are generally superior to CT for this purpose.

Does the location of the tumor within the vagina change the initial imaging choice?

The initial choice of pelvic MRI with contrast remains the same regardless of whether the tumor is in the upper, middle, or lower third of the vagina. However, the location does influence what the radiologist needs to look for. Tumors in the upper vagina often behave like cervical cancer, with drainage to pelvic nodes. Tumors in the lower third can drain to both pelvic and inguinal lymph nodes, so it’s critical to ensure the inguinal region is carefully evaluated on the staging images.

Should I order a chest X-ray for every new diagnosis of vaginal cancer?

A chest X-ray is a reasonable baseline study, but for comprehensive staging of patients with locally advanced disease or suspicious lymph nodes on pelvic imaging, a CT chest (with or without contrast, rated ‘May be appropriate’) or a whole-body FDG-PET/CT is more sensitive for detecting pulmonary metastases. For very early-stage, small tumors, chest imaging may be deferred until after the primary pelvic staging is complete.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026